Last reviewed · How we verify
Placebo (PLA) + MTX, DB
This is a control arm combining placebo with methotrexate (MTX), a disease-modifying antirheumatic drug that inhibits dihydrofolate reductase and reduces inflammation.
This is a control arm combining placebo with methotrexate (MTX), a disease-modifying antirheumatic drug that inhibits dihydrofolate reductase and reduces inflammation. Used for Rheumatoid arthritis (as part of control arm in Phase 3 trial).
At a glance
| Generic name | Placebo (PLA) + MTX, DB |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Disease-modifying antirheumatic drug (DMARD) |
| Target | Dihydrofolate reductase (DHFR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Methotrexate is a folate antagonist that inhibits dihydrofolate reductase, reducing DNA synthesis and cell proliferation, particularly in rapidly dividing immune cells. In rheumatoid arthritis and other autoimmune conditions, MTX suppresses inflammatory cytokine production and T-cell activation. The placebo component serves as the control arm in this Phase 3 trial design.
Approved indications
- Rheumatoid arthritis (as part of control arm in Phase 3 trial)
Common side effects
- Nausea
- Stomatitis
- Elevated liver enzymes
- Bone marrow suppression
- Infection
Key clinical trials
- Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |